Company
Neutrolis
Neutrolis is a clinical-stage biotechnology company developing first-in-class neutrophil extracellular trap (NET)-degrading therapies for autoimmune and inflammatory diseases.
Also known as Neutrolis, Inc.
- Status
- Operatingas of 2026-09-20Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Cambridge, MA, United States
- Founded
- 2017
- Legal name
- Neutrolis, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Neutrolis is a clinical-stage therapeutics company targeting Neutrophil Extracellular Traps (NETs), the pathologic source of extracellular DNA that drives many autoimmune and inflammatory diseases.
Funding snapshot
- Total raised
- $27.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3.5M2025-06-20
Funding rounds
- Round, 2025
- $3.5M2025-06-20, SEC form D sold, 1 investor
- Round, 2025
- $965K2025-02-28, SEC form D sold, 9 investors
- Round, 2021
- $23.1M2021-09-10, SEC form D sold, 28 investors
About the company
- Status notes
- Neutrolis is a clinical-stage biotechnology company developing first-in-class neutrophil extracellular trap (NET)-degrading therapies for autoimmune and inflammatory diseases.
Loading relationship preview